This paper demonstrates a metal–organic framework (MOF) containing photoswitches within the pores as a hybrid solar thermal fuel (STF) and solid–solid phase-change material (ss-PCM). A series of azobenzene-loaded MOFs were synthesized with the general formula Zn2(BDC)2(DABCO)­(AB) x (BDC = 1,4-benzenedicarboxylate, DABCO = 1,4-diazabicyclo[2.2.2]­octane, AB = azobenzene, where x = 1.0, 0.9, 0.5, 0.3), herein named 1⊃AB1.0, 1⊃AB0.9, 1⊃AB0.5, and 1⊃AB0.3 respectively. X-ray powder diffraction, solid-state NMR, and density functional theory calculations were used to explore in detail the structural changes of the host framework that take place upon loading with the AB guest molecules. Differential scanning calorimetry measurements reveal a reversible phase change, which is absent from the evacuated framework. Upon irradiation with 365 nm light, 40% of the AB guests converted from the trans to the higher-energy cis isomeric form in 1⊃AB1.0. The energy stored within the metastable cis isomers is released upon heating and balances the endotherm associated with the phase transition. However, the exotherm associated with the phase transition is retained upon cooling, resulting in a net energy release over a full heating–cooling cycle. The maximum energy density is observed for the fully loaded composite 1⊃AB1.0, which releases 28.9 J g–1. In addition, the cis-AB guests in this composite showed negligible thermal reconversion during 4 months at ambient temperature, with an estimated energy storage half-life of 4.5 years. Further development of MOF-based STF-ss-PCMs could lead to applications for solar energy conversion and storage, and thermal management.

The functionalization of carbon-hydrogen bonds in non-nucleophilic substrates using α-carbonyl sulfoxonium ylides has not been so far investigated, despite the potential safety advantages that such reagents would provide over either diazo compounds or their in situ precursors. Described herein are the cross-coupling reactions of sulfoxonium ylides with C(sp )-H bonds of arenes and heteroarenes in the presence of a rhodium catalyst. The reaction proceeds by a succession of C-H activation, migratory insertion of the ylide into the carbon-metal bond, and protodemetalation, the last step being turnover-limiting. The method is applied to the synthesis of benz[c]acridines when allied to an iridium-catalyzed dehydrative cyclization.

We report an unprecedented selective cleavage of aromatic C-C bonds through the insertion of well-defined iridium complexes into the aromatic ring of simple alkylarenes. The insertion occurs at 50-100 °C without the activation of weaker C-H and C-C bonds and gives unique metallacycles in high yields. Key to the success of this approach is metal-induced deformation of the arene ring, which creates temporary ring strain and promotes direct and selective insertion of the metal into the otherwise inert arene ring C-C bonds.

The delivery of drugs in a controllable fashion is a topic of intense research activity in both academia and industry because of its impact in healthcare. Implantable electronic interfaces for the body have great potential for positive economic, health, and societal impacts; however, the implantation of such interfaces results in inflammatory responses due to a mechanical mismatch between the inorganic substrate and soft tissue, and also results in the potential for microbial infection during complex surgical procedures. Here, we report the use of conducting polypyrrole (PPY)-based coatings loaded with clinically relevant drugs (either an anti-inflammatory, dexamethasone phosphate (DMP), or an antibiotic, meropenem (MER)). The films were characterized and were shown to enhance the delivery of the drugs upon the application of an electrochemical stimulus in vitro, by circa (ca.) 10–30% relative to the passive release from non-stimulated samples. Interestingly, the loading and release of the drugs was correlated with the physical descriptors of the drugs. In the long term, such materials have the potential for application to the surfaces of medical devices to diminish adverse reactions to their implantation in vivo.

Analysis of available studies was limited by variable reporting of primary and secondary outcomes; therefore, it is difficult to draw firm conclusions related to the effectiveness of PAAPs in the management of adult asthma. We found no evidence from randomised controlled trials of additional benefit or harm associated with use of PAAP versus no PAAP, or PAAP plus education versus education alone, but we considered the quality of the evidence to be low or very low, meaning that we cannot be confident in the magnitude or direction of reported treatment effects. In the context of this caveat, we found no observable effect on the primary outcomes of hospital attendance with an asthma exacerbation, asthma symptom scores or adverse events. We recommend further research with a particular focus on key patient-relevant outcomes, including exacerbation frequency and quality of life, in a broad spectrum of adults, including those over 60 years of age.